All Oncology News

NEJM Data Underscores DFS Benefit With Adjuvant Pembrolizumab in Post-Nephrectomy RCC

September 7th 2021

Adjuvant treatment with pembrolizumab led to a significant improvement in disease-free survival compared with placebo after nephrectomy in patients with renal cell carcinoma who are at high risk for recurrence, as underscored by data from the pivotal phase 3 KEYNOTE-564 trial.

ADP-A2AFP SPEAR T Cells Demonstrate Efficacy, Tolerability in Advanced HCC

September 7th 2021

ADP-A2AFPspecific peptide enhanced affinity receptor T cells were associated with an acceptable safety profile and elicited antitumor activity in patients with advanced hepatocellular carcinoma.

Pembrolizumab Plus Lenvatinib Improves Survival in dMMR Endometrial Cancer

September 7th 2021

The combination of pembrolizumab and lenvatinib led to a statistically significant improvement in progression-free survival and overall survival in patients with mismatch repair deficient advanced endometrial cancer following platinum-based chemotherapy.

Management of Toxicities Is Crucial to Immunotherapy Combination Use in HCC

September 7th 2021

David J. Pinato, MD, discusses combination strategies in HCC, how to manage associated toxicities, and how safety profiles can help to inform treatment decisions for this patient population.

Cancer-Specific Mortality Shows Variable Risk Throughout Neuroendocrine Tumors

September 7th 2021

The risk of cancer-specific death was significantly higher than the risk of noncancer death in patients with neuroendocrine tumors, despite the reported heterogeneity by primary tumor site.

Nivolumab Continues to Elicit Durable Responses in Advanced Hepatocellular Carcinoma

September 7th 2021

Nivolumab elicited a prolonged clinical benefit in patients with advanced hepatocellular carcinoma regardless of prior sorafenib.

Overcoming Hurdles to Biosimilar Uptake

September 6th 2021

Sanjiv S. Agarwala, MD, explains that biologics have revolutionized the treatment of serious conditions, including cancer, over the past few decades, however, costs are a pressing issue for all providers and biologics are a major culprit.

Ongoing Research Pushes Precision Oncology Mindset in Gastrointestinal Cancers

September 6th 2021

E. Gabriela Chiorean, MD, discusses some of the recent developments in pancreatic cancer, HCC, and NETs, as well as multidisciplinary approaches for treating these patients.

Investigators Look to Overcome Resistance in Advanced HCC With Triplet Combinations

September 5th 2021

Triplet regimens leveraging novel agents targeted at overcoming mechanisms of resistance in combination with immune checkpoint inhibitors and anti-angiogenic therapies represent the next frontier in hepatocellular carcinoma.

Dr. Pinato on Guidelines for Toxicity Management in HCC

September 5th 2021

David J. Pinato, MD, discusses guidelines for toxicity management in hepatocellular carcinoma (HCC).

Atezolizumab/Bevacizumab Improves OS in Albumin-Bilirubin Grade 1 HCC

September 5th 2021

The combination of atezolizumab and bevacizumab elicited an improved overall survival benefit compared with sorafenib in patients with albumin-bilirubin grade 1 hepatocellular carcinoma, according to findings from an exploratory subgroup analysis of the phase 3 IMbrave150 trial.

High Interferon Signaling and Antigen Presentation Predicts for Response Only in Frontline Advanced HCC

September 5th 2021

Biomarkers of response to immunotherapy, characterized by high interferon signaling and expression of MHC-II related genes, predicted for improved survival in patients with advanced hepatocellular carcinoma following immediate treatment with a PD-1 inhibitor but not in those who had first received treatment with a TKI.

SIRT With Y90 Plus Chemotherapy Extends Survival for Intrahepatic Cholangiocarcinoma

September 4th 2021

The addition of selective internal radiation therapy with Y90 resin microspheres to gemcitabine/cisplatin resulted in a median overall survival of 21.6 months for patients with inoperable intrahepatic cholangiocarcinoma, according to prospective phase 2 data.

Dual Checkpoint Blockade/Ablation Regimens Show Intriguing Activity in Advanced HCC

September 4th 2021

Combining durvalumab and tremelimumab plus transcatheter arterial chemoembolization or radiofrequency ablation was found to be both efficacious and safe as a treatment for patients with advanced hepatocellular carcinoma, according to results of a pilot study.

Predictive Biomarkers for Checkpoint Inhibition Remain Unmet Need in HCC

September 3rd 2021

Josep M. Llovet, MD, discusses the importance of identifying biomarkers of response to checkpoint inhibitors for patients with hepatocellular carcinoma, as well as future research directions.

Pirtobrutinib Exhibits Promising Efficacy in Heavily Pretreated MCL and Other Non-Hodgkin Lymphomas

September 3rd 2021

Pirtobrutinib elicited encouraging responses across all dose levels in patients with mantle cell lymphoma and other non-Hodgkin lymphoma who previously received all classes of available therapy, with benefit observed independent of prior therapy received, according to data from the phase 1/2 BRUIN study.

Single-Agent Trastuzumab Yields Superior Health-Related QoL in HER2+ Breast Cancer

September 3rd 2021

More detrimental effects on health-related quality of life were reported, and lasted for at least 12 months, with the combination of trastuzumab plus chemotherapy compared with trastuzumab alone in older patients with HER2-positive breast cancer, according to an analysis of the phase 3 RESPECT trial.

MYLOX-1 Trial Opens to Evaluate Novel Anti-Fibrotic Agent GB2064 in Myelofibrosis

September 3rd 2021

The phase 2a MYLOX-1 trial is evaluating GB2064, a novel, oral LOXL2 inhibitor, as a potential anti-fibrotic treatment option for patients with myelofibrosis.

Devimistat Plus Gemcitabine/Cisplatin Moves to Phase 2 Setting in Frontline Biliary Tract Cancer

September 3rd 2021

Devimistat in combination with gemcitabine and cisplatin has moved into the phase 2 portion of a phase 1b/2 trial studying the regimen as a first-line treatment for patients with locally advanced unresectable or metastatic biliary tract cancer.

European Commission Expands Ravulizumab-cwvz Approval in Paroxysmal Nocturnal Hemoglobinuria With Pediatric Indication

September 3rd 2021

The European Commission has granted an expanded approval to ravulizumab-cwvz to include children with a body weight of at least 10 kg, as well as adolescents, with paroxysmal nocturnal hemoglobinuria.